# Intracavernous Injection of Botox 100 U for Treatment of PDE5Is Inconvenient Patients With ED

> **NCT04172558** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Benha University** · enrollment: 124 (estimated)

## Conditions studied

- Erectile Dysfunction

## Interventions

- **BIOLOGICAL:** OnabotulinumtoxinA
- **DRUG:** Trimix

## Key facts

- **NCT ID:** NCT04172558
- **Lead sponsor:** Benha University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-10
- **Primary completion:** 2022-10-01
- **Final completion:** 2022-11-01
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2022-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04172558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04172558, "Intracavernous Injection of Botox 100 U for Treatment of PDE5Is Inconvenient Patients With ED". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04172558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*